Specialised non invasive screening to assist in nb: identifying blood flow problems is often the first step. nb: While subsequent minimally invasive angioplasty, a safe, long established day surgery procedure, frequently corrects this condition it isn't necessarily an immediate or universal solution. More than one procedure may be needed along with annual check ups and attention to lifestyle issues.  Also, angioplasty is not suitable for every problematic vein, and vein specialists need to assess individual veins to determine the appropriate course/s of action (if any).
 Kerri Cassidy's journey and associated video library provide a human face to long term studies that support these understandings. For further (primarily Australian) examples click here.

Establishing a Bloodflow Baseline for every CCSVI patient is critical  

Critical to confirming the efficacy of restoring blood flow in the neck veins of persons with MS is the need for specialists in this area to do the nb: standard test to determine if their ballooning procedure (angioplasty) actually did restore blood flow or not. The accepted procedure for determining blood flow is by calculating a venous hemodynamic insufficiency severity score (VHISS). The lower the VHISS score, the better the flow. Thus, if the angioplasty treatment is effectively done, the VHISS score will significantly drop. If this is not done (before or during the procedure) there is no way of knowing if proper blood flow was re-established and remains adequate over time. Failure to gather such fundamental data seriously compromises the ongoing management of this condition (at an individual level) and negates the outcomes of related clinical trials.

 Patient Centred Perspectives
The activities of the Multiple Sclerosis Network of Care (Australia) are underpinned by a comprehensive range of patient centred, evidence based benchmarks. Among these is a model that reflects the outcomes of large, representative population studies identifying the Issues, Needs and Expectations of families living with MS - especially in Australia. This model enables improvements following CCSVI interventions to be compared with broader MS populations.
Large Population Studies reinforce vascular associations with MS Symptoms

In March 2017 this model enabled comparisons between the outcomes of large population studies by Multiple Sclerosis Research Australia (MSRA) in 2012, the (then) Multiple Society of NSW in 2001 and the Multiple Sclerosis International Federation (MSIF) in 2012, with published research relating to the long term outcomes (2011 to 2015) of successfully treating CCSVI conditions with Angioplasty/Venoplasty.